BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26859386)

  • 1. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
    Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
    PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease.
    Farrar AM; Murphy CA; Paterson NE; Oakeshott S; He D; Alosio W; McConnell K; Menalled LB; Ramboz S; Park LC; Howland D; Brunner D
    J Huntingtons Dis; 2014; 3(2):145-58. PubMed ID: 25062858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
    Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
    J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.
    Menalled LB; Kudwa AE; Miller S; Fitzpatrick J; Watson-Johnson J; Keating N; Ruiz M; Mushlin R; Alosio W; McConnell K; Connor D; Murphy C; Oakeshott S; Kwan M; Beltran J; Ghavami A; Brunner D; Park LC; Ramboz S; Howland D
    PLoS One; 2012; 7(12):e49838. PubMed ID: 23284626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.
    Smith GA; Rocha EM; McLean JR; Hayes MA; Izen SC; Isacson O; Hallett PJ
    Hum Mol Genet; 2014 Sep; 23(17):4510-27. PubMed ID: 24728190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
    Carty N; Berson N; Tillack K; Thiede C; Scholz D; Kottig K; Sedaghat Y; Gabrysiak C; Yohrling G; von der Kammer H; Ebneth A; Mack V; Munoz-Sanjuan I; Kwak S
    PLoS One; 2015; 10(4):e0123527. PubMed ID: 25859666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
    Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
    Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington's disease.
    Yu D; Zarate N; White A; Coates D; Tsai W; Nanclares C; Cuccu F; Yue JS; Brown TG; Mansky RH; Jiang K; Kim H; Nichols-Meade T; Larson SN; Gundry K; Zhang Y; Tomas-Zapico C; Lucas JJ; Benneyworth M; Öz G; Cvetanovic M; Araque A; Gomez-Pastor R
    Acta Neuropathol Commun; 2022 Jun; 10(1):83. PubMed ID: 35659303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease.
    Pépin J; Francelle L; Carrillo-de Sauvage MA; de Longprez L; Gipchtein P; Cambon K; Valette J; Brouillet E; Flament J
    Neuroimage; 2016 Oct; 139():53-64. PubMed ID: 27318215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington's disease.
    Zhao Y; Sun X; Qi X
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):319-323. PubMed ID: 30449600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD.
    Rattray I; Smith E; Gale R; Matsumoto K; Bates GP; Modo M
    PLoS One; 2013; 8(4):e60012. PubMed ID: 23593159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.
    Southwell AL; Smith-Dijak A; Kay C; Sepers M; Villanueva EB; Parsons MP; Xie Y; Anderson L; Felczak B; Waltl S; Ko S; Cheung D; Dal Cengio L; Slama R; Petoukhov E; Raymond LA; Hayden MR
    Hum Mol Genet; 2016 Sep; 25(17):3654-3675. PubMed ID: 27378694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
    Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
    Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered mitochondrial Ca
    Yoo H; Park H
    Biochem Biophys Res Commun; 2024 Jul; 716():150010. PubMed ID: 38704892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.